Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck Sharp & Dohme Corp.
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
Immunotherapeutic treatment with Pembrolizumab (antibody) in melanoma patients at high risk of recurrence after complete surgical resection
- To prospectively assess whether post-operative adjuvant therapy with pembrolizumab improves recurrence-free survival, as compared to placebo in high-risk patients with complete resection of Stage II...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
Study of MK-1986 (tedizolid phosphate) in children 3 mo to <12 yr with acute bacterial skin and skin structure infections (ABSSSI)
(1) The primary objective is to use descriptive statistics to evaluate the safety of intravenous (IV) and/or oral 6- or 10-day tedizolid phosphate with 10- or 14-day IV and/or oral comparator in subje...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co
Update Il y a 4 ans
Ph III Trial of Pembrolizumab (MK-3475), pembrolizumab+FP/XP vs. Placebo+FP/XP in Biomarker Select, Advanced Gastric or GEJ Adenocarcinoma Ensayo de fase III de pembrolizumab (MK 3475), pembrolizumab + FP/XP frente a placebo + FP/XP, con detección de biomarcadores, en el adenocarcinoma gástrico o de la UGE avanzado
In subjects with advanced gastric or GEJ adenocarcinoma treated with pembrolizumab monotherapy or a combination of pembrolizumab with chemotherapy versus chemotherapy alone, as first-line treatment in...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
A Phase 3 study in Patients with Type 2 Diabetes Mellitus Studio di fase III su pazienti affetti da diabete mellito di tipo 2
After 24 weeks, to assess the effect of treatment with MK-3102 compared with placebo on A1C. To assess the safety and tolerability of MK-3102. Valutare l’effetto sulla A1C del trattamento con M...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Merck)
Update Il y a 4 ans
MK-3475 vs. Docetaxel in Second-Line Non-Small Cell Lung Cancer
1) To compare the overall survival of previously treated subjects with nonsmall cell lung cancer in the strongly positive PDL1 stratum treated with MK3475 compared to docetaxel. 2) To compare progres...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
A trial to evaluate the pharmacokinetics, safety, and tolerability of MK-7655A in children less than 18 years old with confirmed or suspected gram-negative infections
To obtain plasma PK data and characterize the PK profile of imipenem, cilastatin, and relebactam (REL) following administration of a single IV dose of IMI/REL in pediatric subjects from birth to less ...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
MK-3682 + Ruzasvir for 12 weeks in Subjects with HCV GT1-6 Infection
-To evaluate the efficacy of co-administered MK-3682 (450 mg) + Ruzasvir (180 mg) as assessed by the proportion of subjects achieving sustained virologic response (SVR) at 12 weeks post-treatment (SVR...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
Single Dose of MK-0517 for Prevention of CINV in Pediatric Subjects
Efficacy: To compare the single IV dose of fosaprepitant (in combination with ondansetron) to the ondansetron alone regimen with respect to the efficacy endpoint of Complete Response in the delayed ph...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
PK Study in Adolescents and Young Adults Treated with Glucocorticoids
-To assess the safety and tolerability of single doses of odanacatib in mature adolescents. -To compare plasma pharmacokinetic parameters [AUC0-∞, AUC0-168hr, Cmax, C168hr, Tmax, apparent terminal t½...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
Pediatric PK Study (POS IV and PFS)
To evaluate the pharmacokinetics (PK) of POS IV solution and POS Powder for Oral Suspension (PFS) administered to immunocompromised pediatric subjects (ages 2 years to 17 years)with neutropenia or exp...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next